Rifampicin Transport by OATP1B1 Variants

There is no fulltext present in this item.

Title:	Rifampicin Transport by OATP1B1 Variants
Author(s):	Litjens, C.H.C. ; Heuvel, J.M.W. van den ; Russel, F.G.M. ; Aarnoutse, R.E. ; Brake, L.H.M. te ; Koenderink, J.B.
Publication year:	2020
Source:	Antimicrobial Agents and Chemotherapy, vol. 64, iss. 10, (2020), article e00955-20
ISSN:	0066-4804
DOI:	https://doi.org/10.1128/AAC.00955-20
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/225349
Display more details
Subject:	Radboudumc 11: Renal disorders RIMLS: Radboud Institute for Molecular Life Sciences Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences Tijdelijke code tbv inlezen publicaties Radboudumc - Alleen voor gebruik door Radboudumc
Organization:	Pharmacology-Toxicology Clinical Pharmacy IMM - Institute for Molecules and Materials Radboudumc Extern
Journal title:	Antimicrobial Agents and Chemotherapy
Volume:	vol. 64
Issue:	iss. 10
Article number:	e00955-20
Abstract:	Single nucleotide polymorphisms in the OATP1B1 transporter have been suggested to partially explain the large interindividual variation in rifampicin exposure. HEK293 cells overexpressing wild-type (WT) or OATP1B1 variants 1b, 4, 5, and 15 were used to determine the in vitro rifampicin intrinsic clearance. For OATP1B15 and 15, a 36% and 42% reduction in intrinsic clearance, respectively, compared to WT was found. We consider that these differences in intrinsic clearance most likely have minor clinical implications.